Perimeter Medical Imaging AI (PINK) 2026 Bloom Burton & Co. Healthcare Investor Conference summary

Product innovation and regulatory milestones

• Recently received FDA approval for an AI-enabled imaging device for breast cancer surgery, now entering commercialization phase.

• Clinical trials with hundreds of patients demonstrated improved surgical outcomes and supported FDA approval.

• Proprietary Optical Coherence Tomography (OCT) imaging system combined with AI overlay enables high-resolution, real-time tissue analysis.

• FDA approval allows new label claims, enabling clearer communication with surgeons, hospitals, insurers, and patients.

• AI assistant improves usability, aiming to reduce reoperation rates and expand adoption among surgeons.

Market opportunity and business model

• Targeting a large market with 300,000 annual breast cancer surgeries in the U.S. and millions globally.

• Recurring revenue model based on hardware sales, high-margin consumables, service contracts, and AI software fees.

• Current gross margins are approximately 70% for hardware and 90% for consumables.

• Expansion plans include other cancer types, international markets, and additional applications like biopsy.

• Hospitals use the technology to attract patients and improve satisfaction scores, while insurers benefit from reduced reoperation costs.

Commercial strategy and growth plans

• Transitioning existing customers to the new AI-enabled device and expanding sales force to penetrate new regions.

• Strategic focus on increasing utilization at current sites, expanding within hospital systems, and converting pipeline leads.

• Sales approach includes direct hardware sales, leasing, and minimum volume commitments for consumables.

• Break-even expected within two years, with current monthly burn rate of $400,000-$500,000 and per-procedure revenue of $1,500-$2,000.

• Fundraising underway, aiming to raise CAD 5.6–7.5 million at CAD 0.35 per unit, supporting commercial expansion and a future NASDAQ listing.